Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredicts value

In conclusion, effective clinical response was demonstrated by neoadjuvant letrozole in combination with palbociclib. Compared with PEPI, EPclin might be a better parameter to estimate prognosis after neoadjuvant therapy.

Source: Endocrine-Related Cancer - January 8, 2018 Category: Endocrinology Authors: Chow, L. W. C., Morita, S., Chow, C. Y. C., Ng, W.-K., Toi, M. Tags: Research Source Type: research